TY  - JOUR
AU  - Herrero-Fernández, Inés
AU  - Rosado-Sánchez, Isaac
AU  - Genebat, Miguel
AU  - Tarancón-Díez, Laura
AU  - Rodríguez-Méndez, María Mar
AU  - Pozo-Balado, María Mar
AU  - Lozano, Carmen
AU  - Ruiz-Mateos, Ezequiel
AU  - Leal, Manuel
AU  - Pacheco, Yolanda M
PY  - 2018
DO  - 10.1186/s12967-018-1617-1
UR  - http://hdl.handle.net/10668/12881
T2  - Journal of translational medicine
AB  - Maraviroc-containing combined antiretroviral therapy (MVC-cART) improved the response to the hepatitis B virus (HBV) vaccine in HIV-infected subjects younger than 50 years old. We aimed here to explore the effect of this antiretroviral therapy on...
LA  - en
KW  - Activation
KW  - CD4 T-cell
KW  - Dendritic cells (DC)
KW  - HBV vaccine
KW  - Inflammation
KW  - Ki67
KW  - Maraviroc (MVC)
KW  - Recent thymic emigrants (RTE)
KW  - Treg
KW  - hsCRP
KW  - Adult
KW  - Anti-Retroviral Agents
KW  - Apoptosis
KW  - CD4 Lymphocyte Count
KW  - CD4-Positive T-Lymphocytes
KW  - Cohort Studies
KW  - Dendritic Cells
KW  - Female
KW  - Flow Cytometry
KW  - HIV Infections
KW  - Hepatitis B
KW  - Hepatitis B Vaccines
KW  - Hepatitis B virus
KW  - Humans
KW  - Male
KW  - Maraviroc
KW  - Middle Aged
KW  - Regression Analysis
KW  - T-Lymphocytes, Regulatory
KW  - Treatment Outcome
KW  - Vaccination
KW  - Viral Load
TI  - Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination.
TY  - research article
VL  - 16
ER  -